Talwin™ (pentazocine) – Product discontinuation

- On April 16, 2018, the FDA announced the discontinuation of Hospira's Talwin (pentazocine) 30 mg/mL injection.
    - The product discontinuation is not due to product quality, safety or efficacy concerns.
- Talwin is indicated for the management of pain and used as a preoperative or preanesthetic and as a supplement for surgical anesthesia.
    - Talwin is a Schedule IV controlled substance.
    - Because of the risks of addiction, abuse, and misuse, reserve Talwin for use in patients for whom alternative treatment options have not been tolerated or have not provided adequate analgesia.
- Talwin carries boxed warnings for risks of addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks of profound sedation for concomitant use with benzodiazepines or other central nervous system depressants.
- There are currently no generic manufacturers of this product.
- For additional questions, contact Hospira (now Pfizer injectables) at **1-844-646-4398**.